ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Salt Lake City, UT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Melanoma

Triple Negative Breast Cancer trials near Salt Lake City, UT, USA:

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Magrolimab

Phase 2

Gilead Sciences
Gilead Sciences

Salt Lake City, Utah, United States and 44 other locations

selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple...

Active, not recruiting
Breast Cancer
Renal Cell Carcinoma
Drug: nab-paclitaxel
Drug: Bevacizumab

Phase 2

Infinity Pharmaceuticals
Infinity Pharmaceuticals

Salt Lake City, Utah, United States and 23 other locations

escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer...

Enrolling
Metastatic Breast Cancer
Recurrent Ovarian Carcinoma
Drug: Belinostat
Drug: Ribociclib

Phase 1

Utah System of Higher Education (USHE)
Utah System of Higher Education (USHE)

Salt Lake City, Utah, United States and 1 other location

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Salt Lake City, Utah, United States and 131 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Salt Lake City, Utah, United States and 508 other locations

in participants with solid tumors.Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be remov...

Enrolling
Endometrial Cancer
Non-small Cell Lung Cancer
Drug: PRO1184 intravenous infusion of PRO1184
Drug: PRO1184

Phase 1, Phase 2

ProfoundBio

West Valley City, Utah, United States of America and 21 other locations

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Enrolling
Triple Negative Breast Cancer, TNBC
Small Cell Lung Cancer, SCLC
Drug: JAB-2485 (Aurora A inhibitor)

Phase 1, Phase 2

Jacobio Pharmaceuticals

Salt Lake City, Utah, United States and 4 other locations

This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, PK, and antitumor activity of PRO1107 in patients wit...

Enrolling
Endometrial Cancer
Non-small Cell Lung Cancer
Drug: PRO1107

Phase 1, Phase 2

ProfoundBio

Salt Lake City, Utah, United States and 3 other locations

preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Es...

Enrolling
Triple Negative Breast Neoplasms
Platinum-resistant Ovarian Cancer
Drug: NKT3447

Phase 1

NiKang Therapeutics

West Valley City, Utah, United States of America and 4 other locations

besides treating your disease.Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed w...

Enrolling
Gastric Cancer
Triple Negative Breast Neoplasms
Drug: SGN-PDL1V
Drug: pembrolizumab

Phase 1

Seagen
Seagen

West Valley City, Utah, United States and 22 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems